Three-dimensional structure of a Nanobody® (modeled on the VHH with pdb-code 1U0Q, Cambillau et al). The target molecule is recognized by the surface formed by three hypervariable regions located at the top of the molecule (in green, cyan and blue). Hallmarks, amino acid residues that further differentiate a camelid VHH from a human VH, can be located at different positions within the framework regions, and here are coloured red, pink and magenta.

Home INVESTOR RELATIONS NEWSROOM > PRESS RELEASES

Press Releases

22/12/2009

ABLYNX DEMONSTRATES PROOF-OF-CONCEPT BY BIOMARKER FOR ITS ANTI-THROMBOTIC ALX-0081

14/12/2009

ABLYNX INITIATES PHASE I FOR ALX-0141 (ANTI-RANKL)

02/12/2009

ABLYNX WILL RECEIVE FURTHER MILESTONE PAYMENTS OF €3 MILLION AS PART OF ITS STRATEGIC ALLIANCE WITH BOEHRINGER INGELHEIM

26/11/2009

ABLYNX WILL PRESENT AT PIPER JAFFRAY 21ST ANNUAL HEALTH CARE CONFERENCE IN NEW YORK

23/11/2009

ABLYNX RECEIVES €1.1 MILLION GRANT TO FURTHER DEVELOP NEW ROUTES OF ADMINISTRATION FOR NANOBODIES®

18/11/2009

ABLYNX ACHIEVES THIRD MILESTONE IN DRUG DISCOVERY AND DEVELOPMENT COLLABORATION

10/11/2009

ABLYNX PROVIDES BUSINESS UPDATE FOR THE THIRD QUARTER 2009

30/10/2009

ABLYNX ANNOUNCES WARRANT EXERCISE

23/10/2009

ABLYNX WINS AWARD FOR 'MOST SUCCESSFUL EARLY PHASE TRIAL'

19/10/2009

ABLYNX PROVIDES AN R&D UPDATE AND ANNOUNCES RECENT TECHNOLOGY ADVANCES

12/10/2009

ABLYNX AND DOMANTIS SETTLE THEIR DISPUTE AND STOP THE ARBITRATION PROCESS

05/10/2009

ABLYNX RECEIVES A SECOND MILESTONE PAYMENT FROM NANOBODY® DISCOVERY AND DEVELOPMENT ALLIANCE

01/10/2009

ABLYNX RECEIVES MILESTONE PAYMENT AS PART OF ITS STRATEGIC ALLIANCE WITH BOEHRINGER INGELHEIM

30/09/2009

WYETH PHARMACEUTICALS INITIATES PHASE II AND PAYS ABLYNX ANOTHER MILESTONE IN THE TNF-alpha NANOBODY® COLLABORATION

24/09/2009

DISCLOSURE IN ACCORDANCE WITH THE TRANSPARENCY LEGISLATION OF 2 MAY 2007

15/09/2009

ABLYNX ANNOUNCES WEBCAST OF ITS PRESENTATION AT THE UBS GLOBAL LIFE SCIENCES CONFERENCE IN NEW YORK

01/09/2009

ABLYNX INITIATES PHASE II CLINICAL TRIAL FOR ALX-0081

27/08/2009

ABLYNX ANNOUNCES HALF-YEAR RESULTS FOR 2009

24/08/2009

ABLYNX WILL ANNOUNCE HALF-YEAR RESULTS FOR 2009 WITH WEBCAST

18/08/2009

ABLYNX ANNOUNCES POSITIVE PHASE I RESULTS FOR SUBCUTANEOUS ADMINISTRATION OF ITS ANTI-THROMBOTIC NANOBODY® (ALX-0681)

28/07/2009

ABLYNX ANNOUNCES WARRANT EXERCISE

02/07/2009

ABLYNX PROMOTED TO THE BELGIAN MID-CAP INDEX

29/06/2009

ABLYNX ANNOUNCES A NOVEL PRECLINICAL DEVELOPMENT CANDIDATE TARGETING IL6R

26/06/2009

ABLYNX WINS EUROPEAN MEDISCIENCE AWARD FOR BEST TECHNOLOGY

25/05/2009

Ablynx appoints Medical Director and Business Development Director

07/05/2009

ABLYNX ANNOUNCES THAT ITS vWF NANOBODY® PROGRAMME HAS BEEN GRANTED ORPHAN DRUG DESIGNATION AND PROVIDES A BUSINESS UPDATE FOR THE FIRST QUARTER 2009

30/03/2009

ABLYNX REPORTS DETAILED POSITIVE PHASE Ib RESULTS FOR ITS ANTI-THROMBOTIC NANOBODY® ALX-0081

24/02/2009

ABLYNX ANNOUNCES 2008 FULL YEAR RESULTS

18/02/2009

ABLYNX WILL ANNOUNCE FULL YEAR RESULTS FOR 2008 WITH WEBCAST

05/02/2009

ABLYNX ANNOUNCES SECOND EXTENSION OF ITS NANOBODY® DRUG DISCOVERY AND DEVELOPMENT ALLIANCE

03/02/2009

ABLYNX RECEIVES €3 MILLION IN MILESTONE PAYMENTS AS PART OF ITS STRATEGIC ALLIANCE WITH BOEHRINGER INGELHEIM

20/01/2009

ABLYNX EXPANDS ITS MUSCULOSKELETAL PORTFOLIO BY TAKING P&G PHARMACEUTICALS' PROGRAMME IN-HOUSE

14/01/2009

ABLYNX ANNOUNCES TECHNICAL ADVANCES IN ITS NANOBODY® PLATFORM TECHNOLOGY: ENHANCED BENEFITS FROM PULMONARY DELIVERY AND HALF-LIFE EXTENSION

12/01/2009

ABLYNX ANNOUNCES WEBCAST OF ITS PRESENTATION AT THE 27TH ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE

08/01/2009

ABLYNX STRENGTHENS MANAGEMENT TEAM WITH THE APPOINTMENT OF DR DEBBIE LAW AS CHIEF SCIENTIFIC OFFICER

 

Press releases

News archive

Email alerts

If you would like to receive updates on the company news, please
click here